{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T18:15:09Z","timestamp":1778696109447,"version":"3.51.4"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004329","name":"The Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["J3\\u201360065"],"award-info":[{"award-number":["J3\\u201360065"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"The Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["ARIS P1\\u20130245"],"award-info":[{"award-number":["ARIS P1\\u20130245"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"The Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["101079113"],"award-info":[{"award-number":["101079113"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004329","name":"The Slovenian Research and Innovation Agency","doi-asserted-by":"publisher","award":["J3\\u20134045"],"award-info":[{"award-number":["J3\\u20134045"]}],"id":[{"id":"10.13039\/501100004329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.biopha.2026.119010","type":"journal-article","created":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T19:46:18Z","timestamp":1768679178000},"page":"119010","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Gene expression profiles associated with carboplatin chemoresistance in high-grade serous ovarian cancer: insights from 2D and 3D models"],"prefix":"10.1016","volume":"195","author":[{"given":"Vesna Kokondoska","family":"Grgi\u010d","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2729-0071","authenticated-orcid":false,"given":"Nika","family":"Marolt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajla","family":"Kubat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara","family":"Dokmanovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2855-2793","authenticated-orcid":false,"given":"Katja","family":"Kolo\u0161a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0418-2986","authenticated-orcid":false,"given":"Ivana","family":"Jov\u010devska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tea Lani\u0161nik","family":"Ri\u017ener","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biopha.2026.119010_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.biopha.2026.119010_bib2","doi-asserted-by":"crossref","DOI":"10.1172\/JCI174013","article-title":"Biology-driven therapy advances in high-grade serous ovarian cancer","volume":"134","author":"Wang","year":"2024","journal-title":"J. Clin. Investig."},{"issue":"4","key":"10.1016\/j.biopha.2026.119010_bib3","first-page":"284","article-title":"Ovarian cancer statistics","volume":"68","author":"Torre","year":"2018","journal-title":"2018. CA A Cancer Journal Clinicians"},{"issue":"5","key":"10.1016\/j.biopha.2026.119010_bib4","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/annonc\/mdz062","article-title":"ESMO\u2013ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"30","author":"Colombo","year":"2019","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119010_bib5","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1038\/s41467-022-31919-8","article-title":"A multi-omic dissection of super-enhancer driven oncogenic gene expression programs in ovarian cancer","volume":"13","author":"Kelly","year":"2022","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.biopha.2026.119010_bib6","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00428-012-1203-5","article-title":"Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features","volume":"460","author":"Prat","year":"2012","journal-title":"Virchows Arch."},{"issue":"7","key":"10.1016\/j.biopha.2026.119010_bib7","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s00018-022-04395-y","article-title":"Preclinical models of epithelial ovarian cancer: practical considerations and challenges for a meaningful application","volume":"79","author":"Ciucci","year":"2022","journal-title":"Cell Mol. Life Sci."},{"issue":"7353","key":"10.1016\/j.biopha.2026.119010_bib8","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Bell","year":"2011","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.biopha.2026.119010_bib9","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1038\/s41598-020-59671-3","article-title":"Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma","volume":"10","author":"Takaya","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119010_bib10","doi-asserted-by":"crossref","DOI":"10.1172\/JCI65833","article-title":"Prognostically relevant gene signatures of high-grade serous ovarian carcinoma","author":"Verhaak","year":"2012","journal-title":"J. Clin. Investig."},{"issue":"9","key":"10.1016\/j.biopha.2026.119010_bib11","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1136\/ijgc-2019-000624","article-title":"Management of recurrent ovarian cancer: when platinum-based regimens are not a therapeutic option","volume":"29","author":"Bergamini","year":"2019","journal-title":"Int J. Gynecol. Cancer"},{"key":"10.1016\/j.biopha.2026.119010_bib12","unstructured":"Todd, R.C., Structural and functional consequences of platinum anticancer drug binding to free and nucleosomal DNA, in Department of Chemistry. 2010, Massachusetts Institute of Technology."},{"key":"10.1016\/j.biopha.2026.119010_bib13","series-title":"Carboplatin: molecular mechanisms of action associated with chemoresistance","author":"Sousa","year":"2022"},{"issue":"5","key":"10.1016\/j.biopha.2026.119010_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/biom14050585","article-title":"Oncogenic Pathways and Targeted Therapies in Ovarian Cancer","volume":"14","author":"Lliberos","year":"2024","journal-title":"Biomolecules"},{"issue":"7","key":"10.1016\/j.biopha.2026.119010_bib15","doi-asserted-by":"crossref","first-page":"209","DOI":"10.4331\/wjbc.v1.i7.209","article-title":"Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action","volume":"1","author":"Itamochi","year":"2010","journal-title":"World J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.biopha.2026.119010_bib16","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.7150\/thno.69424","article-title":"Platinum-based drugs for cancer therapy and anti-tumor strategies","volume":"12","author":"Zhang","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.biopha.2026.119010_bib17","unstructured":"A. Randomized, Placebo-controlled, Double-blind, Multicenter Phase 1b\/2 Study of Avelumab With or Without Entinostat in Patients With Advanced Epithelial Ovarian Cancer Which Has Progressed or Recurred After First-line Platinum-based Chemotherapy and at Least Two Subsequent Lines of Treatment With a Safety Lead-in, D.G.Merck KgaA and Pfizer, Editors. 2016."},{"key":"10.1016\/j.biopha.2026.119010_bib18","doi-asserted-by":"crossref","first-page":"782","DOI":"10.3389\/fonc.2020.00782","article-title":"PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?","volume":"10","author":"Franzese","year":"2020","journal-title":"Front Oncol."},{"key":"10.1016\/j.biopha.2026.119010_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.103145","article-title":"Efficacy and safety of PARP inhibitors in the treatment of advanced ovarian cancer: An updated systematic review and meta-analysis of randomized controlled trials","volume":"157","author":"Hao","year":"2021","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.biopha.2026.119010_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18091967","article-title":"Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer","volume":"18","author":"Loizzi","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119010_bib21","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231221336","article-title":"Combined use of Anlotinib with chemotherapy in patients with advanced ovarian cancer: a real-world cohort study and meta-analysis","volume":"16","author":"Hong","year":"2024","journal-title":"Ther. Adv. Med Oncol."},{"issue":"19","key":"10.1016\/j.biopha.2026.119010_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21197379","article-title":"Combined Poziotinib with Manidipine Treatment Suppresses Ovarian Cancer Stem-Cell Proliferation and Stemness","volume":"21","author":"Lee","year":"2020","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2026.119010_bib23","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1038\/s41467-025-58440-y","article-title":"Neo-adjuvant pembrolizumab in stage IV high-grade serous ovarian cancer: the phase II Neo-Pembro trial","volume":"16","author":"Aronson","year":"2025","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.biopha.2026.119010_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103666","article-title":"PD-1\/PD-L1 immune checkpoint blockade in ovarian cancer: Dilemmas and opportunities","volume":"28","author":"Peng","year":"2023","journal-title":"Drug Discov. Today"},{"issue":"7","key":"10.1016\/j.biopha.2026.119010_bib25","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1158\/2326-6066.CIR-24-1050","article-title":"Targeting Cancer-Associated Glycosylation for Adoptive T-cell Therapy of Solid Tumors","volume":"13","author":"Zingg","year":"2025","journal-title":"Cancer Immunol. Res"},{"issue":"1","key":"10.1016\/j.biopha.2026.119010_bib26","doi-asserted-by":"crossref","DOI":"10.1172\/JCI174013","article-title":"Biology-driven therapy advances in high-grade serous ovarian cancer","volume":"134","author":"Wang","year":"2024","journal-title":"J. Clin. Investig."},{"issue":"3","key":"10.1016\/j.biopha.2026.119010_bib27","doi-asserted-by":"crossref","first-page":"339","DOI":"10.15171\/apb.2017.041","article-title":"The Different Mechanisms of Cancer Drug Resistance: A Brief Review","volume":"7","author":"Mansoori","year":"2017","journal-title":"Adv. Pharm. Bull."},{"issue":"10","key":"10.1016\/j.biopha.2026.119010_bib28","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nrc3144","article-title":"Rethinking ovarian cancer: recommendations for improving outcomes","volume":"11","author":"Vaughan","year":"2011","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.biopha.2026.119010_bib29","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S0025-6196(11)61196-8","article-title":"Current management strategies for ovarian cancer","volume":"82","author":"Aletti","year":"2007","journal-title":"Mayo Clin. Proc."},{"issue":"6","key":"10.1016\/j.biopha.2026.119010_bib30","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrc2644","article-title":"The biology of ovarian cancer: new opportunities for translation","volume":"9","author":"Bast","year":"2009","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2026.119010_bib31","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer Journal Clinicians"},{"issue":"2","key":"10.1016\/j.biopha.2026.119010_bib32","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.soncn.2019.02.001","article-title":"Ovarian Cancer: An Integrated Review","volume":"35","author":"Stewart","year":"2019","journal-title":"Semin. Oncol. Nurs."},{"key":"10.1016\/j.biopha.2026.119010_bib33","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.critrevonc.2017.06.007","article-title":"Ovarian cancer: Novel molecular aspects for clinical assessment","volume":"117","author":"Palmirotta","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119010_bib34","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.ajpath.2015.11.011","article-title":"Ie, The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded.","volume":"186","author":"Kurman","year":"2016","journal-title":"Am. J. Pathol."},{"issue":"2","key":"10.1016\/j.biopha.2026.119010_bib35","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2217\/3dp-2019-0004","article-title":"3D bioprinting for oncology applications","volume":"3","author":"Liu","year":"2019","journal-title":"J. 3D Print. Med"},{"issue":"8","key":"10.1016\/j.biopha.2026.119010_bib36","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/jamainternmed.2020.2250","article-title":"Limitations in Clinical Trials Leading to Anticancer Drug Approvals by the US Food and Drug Administration","volume":"180","author":"Hilal","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"30","key":"10.1016\/j.biopha.2026.119010_bib37","doi-asserted-by":"crossref","first-page":"7389","DOI":"10.1016\/j.biomaterials.2013.06.009","article-title":"A bioengineered 3D ovarian cancer model for the assessment of peptidase-mediated enhancement of spheroid growth and intraperitoneal spread","volume":"34","author":"Loessner","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.biopha.2026.119010_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17040700","article-title":"The Evolution of Anticancer 3D In Vitro Models: The Potential Role of Machine Learning and AI in the Next Generation of Animal-Free Experiments","volume":"17","author":"Momoli","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2026.119010_bib39","doi-asserted-by":"crossref","first-page":"1146477","DOI":"10.3389\/fonc.2023.1146477","article-title":"Towards a New 3Rs Era in the construction of 3D cell culture models simulating tumor microenvironment","volume":"13","author":"Zhang","year":"2023","journal-title":"Front Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119010_bib40","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/ame2.12077","article-title":"The promises and challenges of patient-derived tumor organoids in drug development and precision oncology","volume":"2","author":"Granat","year":"2019","journal-title":"Anim. Model Exp. Med"},{"issue":"8","key":"10.1016\/j.biopha.2026.119010_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24086949","article-title":"Applications and Advances of Multicellular Tumor Spheroids: Challenges in Their Development and Analysis","volume":"24","author":"Mitrakas","year":"2023","journal-title":"Int J. Mol. Sci."},{"issue":"15","key":"10.1016\/j.biopha.2026.119010_bib42","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.2174\/1381612824666180404152304","article-title":"Comparative Assay of 2D and 3D Cell Culture Models: Proliferation, Gene Expression and Anticancer Drug Response","volume":"24","author":"Souza","year":"2018","journal-title":"Curr. Pharm. Des."},{"issue":"269","key":"10.1016\/j.biopha.2026.119010_bib43","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal"},{"issue":"7353","key":"10.1016\/j.biopha.2026.119010_bib44","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Cancer Genome Atlas Research, N., Integrated genomic analyses of ovarian carcinoma.","volume":"474","year":"2011","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.biopha.2026.119010_bib45","doi-asserted-by":"crossref","first-page":"20778","DOI":"10.1021\/acsami.2c03706","article-title":"Evaluation of Proton-Induced DNA Damage in 3D-Engineered Glioblastoma Microenvironments","volume":"14","author":"Akolawala","year":"2022","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"3","key":"10.1016\/j.biopha.2026.119010_bib46","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.6729","article-title":"BRCA1, BRCA2, and TP53 germline and somatic variants and clinicopathological characteristics of Brazilian patients with epithelial ovarian cancer","volume":"13","author":"Richau","year":"2024","journal-title":"Cancer Med"},{"issue":"7","key":"10.1016\/j.biopha.2026.119010_bib47","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/s41416-023-02140-1","article-title":"Transcriptome analysis of newly established carboplatin-resistant ovarian cancer cell model reveals genes shared by drug resistance and drug-induced EMT","volume":"128","author":"Kralj","year":"2023","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2026.119010_bib48","doi-asserted-by":"crossref","first-page":"11677","DOI":"10.1038\/s41598-019-47871-5","article-title":"Matrix Metalloproteinase Expressions Play Important role in Prediction of Ovarian Cancer Outcome","volume":"9","author":"Wang","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119010_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.biocel.2022.106191","article-title":"Wnt antagonist as therapeutic targets in ovarian cancer","volume":"145","author":"Y","year":"2022","journal-title":"Int J. Biochem Cell Biol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119010_bib50","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13048-020-00676-x","article-title":"Expression of metalloproteinases MMP-2 and MMP-9 is associated to the presence of androgen receptor in epithelial ovarian tumors","volume":"13","author":"Morales-Vasquez","year":"2020","journal-title":"J. Ovarian Res"},{"key":"10.1016\/j.biopha.2026.119010_bib51","unstructured":"R Studio Team, RStudio: Integrated Development Environment for R. 2016."},{"issue":"6","key":"10.1016\/j.biopha.2026.119010_bib52","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/2041-210X.13384","article-title":"metan: An R package for multi-environment trial analysis","volume":"11","author":"Olivoto","year":"2020","journal-title":"Methods Ecol. Evol."},{"issue":"7","key":"10.1016\/j.biopha.2026.119010_bib53","doi-asserted-by":"crossref","DOI":"10.2196\/27633","article-title":"Web-Based Survival Analysis Tool Tailored for Medical Research (KMplot): Development and Implementation","volume":"23","author":"L\u00e1nczky","year":"2021","journal-title":"J. Med Internet Res"},{"issue":"3","key":"10.1016\/j.biopha.2026.119010_bib54","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s11357-023-00742-4","article-title":"Discovery and ranking of the most robust prognostic biomarkers in serous ovarian cancer","volume":"45","author":"Gy\u0151rffy","year":"2023","journal-title":"GeroScience"},{"issue":"8","key":"10.1016\/j.biopha.2026.119010_bib55","first-page":"1197","article-title":"Biological characterization including sensitivity to mitomycin C of cultured human ovarian cancers (author's transl)","volume":"33","author":"Motoyama","year":"1981","journal-title":"Nihon Sanka Fujinka Gakkai Zasshi"},{"issue":"4","key":"10.1016\/j.biopha.2026.119010_bib56","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/ijc.2910530415","article-title":"Establishment and characterization of 7 ovarian carcinoma cell lines and one granulosa tumor cell line: growth features and cytogenetics","volume":"53","author":"van den Berg-Bakker","year":"1993","journal-title":"Int J. Cancer"},{"issue":"4","key":"10.1016\/j.biopha.2026.119010_bib57","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1373\/clinchem.2008.112797","article-title":"The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments","volume":"55","author":"Bustin","year":"2009","journal-title":"Clin. Chem."},{"key":"10.1016\/j.biopha.2026.119010_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.743403","article-title":"In the Model Cell Lines of Moderately and Poorly Differentiated Endometrial Carcinoma, Estrogens Can Be Formed via the Sulfatase Pathway","volume":"8","author":"Pavli\u010d","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.biopha.2026.119010_bib59","article-title":"Targeting estrogen metabolism in high-grade serous ovarian cancer shows promise to overcome platinum resistance","volume":"177","author":"Marolt","year":"2024","journal-title":"Biomed. amp Pharmacother."},{"key":"10.1016\/j.biopha.2026.119010_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2024.110977","article-title":"Genotoxicity and heating Performance of V(x)Fe(3-x)O(4) nanoparticles in Health applications","volume":"394","author":"Sanz-Sague","year":"2024","journal-title":"Chem. Biol. Inter."},{"issue":"7","key":"10.1016\/j.biopha.2026.119010_bib61","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.7314\/APJCP.2013.14.7.4107","article-title":"Prognostic value of MMP-9 in ovarian cancer: a meta-analysis","volume":"14","author":"Li","year":"2013","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"1","key":"10.1016\/j.biopha.2026.119010_bib62","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cell.2010.03.015","article-title":"Matrix metalloproteinases: regulators of the tumor microenvironment","volume":"141","author":"Kessenbrock","year":"2010","journal-title":"Cell"},{"issue":"3-4","key":"10.1016\/j.biopha.2026.119010_bib63","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s10555-007-9089-4","article-title":"The other side of MMPs: protective roles in tumor progression","volume":"26","author":"Martin","year":"2007","journal-title":"Cancer Metastas.. Rev."},{"key":"10.1016\/j.biopha.2026.119010_bib64","article-title":"High-Throughput Platform for Patient-Derived, Small Cell Number, Three-Dimensional","author":"Mehta","year":"2014","journal-title":"Ovarian Cancer Spheroids"},{"issue":"6","key":"10.1016\/j.biopha.2026.119010_bib65","doi-asserted-by":"crossref","DOI":"10.1002\/btpr.3034","article-title":"Establishment and characterization of an in vitro 3D ovarian cancer model for drug screening assays","volume":"36","author":"Tofani","year":"2020","journal-title":"Biotechnol. Prog."},{"issue":"36","key":"10.1016\/j.biopha.2026.119010_bib66","doi-asserted-by":"crossref","first-page":"14480","DOI":"10.1021\/acs.analchem.4c02592","article-title":"Assessing Drug Uptake and Response Differences in 2D and 3D Cellular Environments Using Stimulated Raman Scattering Microscopy","volume":"96","author":"Xu","year":"2024","journal-title":"Anal. Chem."},{"key":"10.1016\/j.biopha.2026.119010_bib67","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.3389\/fbioe.2023.1135374","article-title":"3D dynamic cultures of HGSOC organoids to model innovative and standard therapies","volume":"11","author":"Cavarzerani","year":"2023","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119010_bib68","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s12951-020-00646-x","article-title":"Three-dimensional culture and clinical drug responses of a highly metastatic human ovarian cancer HO-8910PM cells in nanofibrous microenvironments of three hydrogel biomaterials","volume":"18","author":"Song","year":"2020","journal-title":"J. Nanobiotechnology"},{"issue":"1","key":"10.1016\/j.biopha.2026.119010_bib69","doi-asserted-by":"crossref","first-page":"18183","DOI":"10.1038\/s41598-021-97434-w","article-title":"Carboplatin response in preclinical models for ovarian cancer: comparison of 2D monolayers, spheroids, ex vivo tumors and in vivo models","volume":"11","author":"Brodeur","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119010_bib70","doi-asserted-by":"crossref","DOI":"10.3390\/biom11111711","article-title":"Epigenetic Therapy Augments Classic Chemotherapy in Suppressing the Growth of 3D High-Grade Serous Ovarian Cancer Spheroids over an Extended Period of Time","volume":"11","author":"Bilbao","year":"2021","journal-title":"Biomolecules"},{"issue":"12","key":"10.1016\/j.biopha.2026.119010_bib71","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0244549","article-title":"Carboplatin sensitivity in epithelial ovarian cancer cell lines: The impact of model systems","volume":"15","author":"Patra","year":"2020","journal-title":"PLoS One"},{"issue":"13","key":"10.1016\/j.biopha.2026.119010_bib72","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15133350","article-title":"Transcriptional Landscape of 3D vs. 2D Ovarian Cancer Cell Models","volume":"15","author":"Kerslake","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"19","key":"10.1016\/j.biopha.2026.119010_bib73","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15194846","article-title":"Three-Dimensional In Vitro Tumor Spheroid Models for Evaluation of Anticancer Therapy: Recent Updates","volume":"15","author":"Nayak","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2026.119010_bib74","article-title":"An Omentum-inspired 3D PEG Hydrogel for Identifying ECM-drivers of Drug Resistant Ovarian Cancer","author":"Brooks","year":"2019","journal-title":"bioRxiv"},{"issue":"1","key":"10.1016\/j.biopha.2026.119010_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2021.101086","article-title":"Building invitro 3D human multicellular models of high-grade serous ovarian cancer","volume":"3","author":"Malacrida","year":"2022","journal-title":"STAR Protoc."},{"issue":"12","key":"10.1016\/j.biopha.2026.119010_bib76","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1016\/j.devcel.2023.04.012","article-title":"A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids","volume":"58","author":"Senkowski","year":"2023","journal-title":"Dev. Cell"},{"issue":"6_ement","key":"10.1016\/j.biopha.2026.119010_bib77","article-title":"Abstract 4249: Establishment and analysis of patient-derived high-grade serous ovarian cancer organoids for disease modeling and drug testing","volume":"84","author":"Kallunki","year":"2024","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2026.119010_bib78","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41392-021-00648-7","article-title":"DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"issue":"1","key":"10.1016\/j.biopha.2026.119010_bib79","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ygyno.2019.11.020","article-title":"Patient-derived explants, xenografts and organoids: 3-dimensional patient-relevant pre-clinical models in endometrial cancer","volume":"156","author":"Collins","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119010_bib80","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nrm3758","article-title":"Molecular mechanisms of epithelial\u2013mesenchymal transition","volume":"15","author":"Lamouille","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119010_bib81","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cell.2016.06.028","article-title":"EMT: 2016","volume":"166","author":"Nieto","year":"2016","journal-title":"Cell"},{"issue":"16_","key":"10.1016\/j.biopha.2026.119010_bib82","article-title":"Ex vivo tumor testing platform for predicting clinical response to platinum-based therapy in patients with high grade serous ovarian cancer","volume":"41","author":"Ottevanger","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119010_bib83","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13048-023-01145-x","article-title":"Insights into high-grade serous carcinoma pathobiology using three-dimensional culture model systems","volume":"16","author":"Tomas","year":"2023","journal-title":"J. Ovarian Res"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226000429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226000429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:39:33Z","timestamp":1778693973000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226000429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":83,"alternative-id":["S0753332226000429"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119010","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene expression profiles associated with carboplatin chemoresistance in high-grade serous ovarian cancer: insights from 2D and 3D models","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119010"}}